Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buparlisib in Recurrent/Refractory PCNSL and SCNSL
NCT02301364Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2014
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of buparlisib in primary central nervous system lymphoma (PCNSL) and secondary central nervous system lymphoma (SCNSL), sponsored by Memorial Sloan Kettering Cancer Center. Started Nov 2014; status: completed.
02
Drugs
buparlisib
03
Conditions
primary central nervous system lymphoma (PCNSL)secondary central nervous system lymphoma (SCNSL)
Beyond the preview
Go deeper on NCT02301364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02301364.